Related Experiment Videos
Standardizing 8-methoxypsoralen plasma profiles by using an emulsion form
Abstract:
Uniform 8-methoxypsoralen (8-MOP) absorption from the gastrointestinal tract is necessary to avoid day-to-day variations in 8-MOP plasma levels when treating patients with psoriasis by photochemotherapy. Because of its low water solubility, particle size and crystal form of the 8-MOP can significantly influence its bioavailability. The presentation form is also important, as is shown by the present study in which 8-MOP plasma levels were compared in thirty patients after oral administration in three different forms: formulation A consisted of gelatin capsules containing 8-MOP with a mean particle size of 200 mu; formulation B consisted of gelatin capsules containing 8-MOP in microcrystalline form with particle size between 20 mu and 30 mu; formulation C contained the same microcrystalline 8-MOP but in an emulsion base. Significantly higher plasma levels were found with formulations B and C than with formulation A. Furthermore, the individual differences in plasma profiles were markedly less with the emulsion base than with the capsule forms. Therefore, the clinical use of 8-MOP in emulsion form would constitute a major step in 8-MOP dose standardization and could lead to better control of subjective side effects and better therapeutic results.
Insights
Uniform absorption of 8-methoxypsoralen (8-MOP) is crucial for photochemotherapy. Microcrystalline 8-MOP in an emulsion base significantly improved plasma levels and reduced variability compared to standard capsules.
Area of Science:
- Pharmacology
- Dermatology
- Drug Delivery
Background:
- Consistent 8-methoxypsoralen (8-MOP) absorption is vital for effective psoriasis photochemotherapy.
- Low water solubility of 8-MOP affects its bioavailability, influenced by particle size and crystal form.
- Drug formulation significantly impacts 8-MOP plasma concentration and therapeutic outcomes.
Purpose of the Study:
- To evaluate the impact of different 8-methoxypsoralen (8-MOP) formulations on plasma levels and bioavailability.
- To compare oral 8-MOP absorption from standard capsules versus microcrystalline forms in an emulsion base.
- To determine the optimal formulation for standardized dosing and improved therapeutic efficacy in photochemotherapy.
Main Methods:
- Thirty patients with psoriasis received oral 8-methoxypsoralen (8-MOP) in three distinct formulations.
- Formulation A: Gelatin capsules with 200 μm 8-MOP particles.
- Formulations B and C: Microcrystalline 8-MOP (20-30 μm) in gelatin capsules (B) and an emulsion base (C).
Main Results:
- Formulations B (microcrystalline capsules) and C (emulsion base) yielded significantly higher 8-MOP plasma levels than Formulation A (standard capsules).
- The emulsion base (Formulation C) demonstrated markedly reduced inter-individual variability in plasma profiles compared to capsule forms (A and B).
- Microcrystalline 8-MOP, particularly in an emulsion, enhances bioavailability and consistency of plasma levels.
Conclusions:
- Microcrystalline 8-methoxypsoralen (8-MOP) in an emulsion base offers superior absorption and reduced variability for photochemotherapy.
- This formulation advancement is key for standardizing 8-MOP dosage, potentially improving treatment efficacy and reducing side effects.
- Emulsion-based 8-MOP represents a significant improvement for psoriasis photochemotherapy management.